Jeffrey W. Church

Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer), Imunon, Inc.

A later filing names a successor. First published here October 28, 2026; built from records as of October 28, 2026.

Jeffrey W. Church signed the annual report of Imunon, Inc. on Form 10-K as Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer), filed March 31, 2026.¹ A later filing by Imunon, Inc., made on June 30, 2026, names Josh Blacher as its interim chief financial officer; the record holds no filing that reports the end of Jeffrey W. Church's tenure.

Seats

The seat in the record

Company	Title as filed	Standing	Filings
Imunon, Inc. (IMNN) Pharmaceutical Preparations	Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)	A later filing names a successor Josh Blacher, filed June 30, 2026 (filing)	1

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

March 31, 202610-K filed
Jeffrey W. Church signed the annual report of Imunon, Inc. on Form 10-K as Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer), filed March 31, 2026.
/s/ JEFFREY W. CHURCH Chief Financial Officer March 31, 2026 (Jeffrey W. Church) (Principal Financial Officer and Principal Accounting Officer)
[1] Annual report on Form 10-K by Imunon, Inc., filed with the SEC on March 31, 2026. Read the filing. The record at CFO Tribune.

Sources

Annual report on Form 10-K, Imunon, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed March 31, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Jeffrey W. Church wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.